Journal of Cystic Fibrosis
Издатель: Elsevier · ISSN 1569-1993 · 74 статей
- Association of dental diseases with pulmonary outcomes in a multicenter cohort of adolescents and young adults with CF
- Ocular surface and anterior segment changes in cystic fibrosis: evidence of a corneal and conjunctival epithelial phenotype - a case-control study
- Factors associated with adherence to inhaled medicines in cystic fibrosis following the introduction of elexacaftor/tezacaftor/ivacaftor using electronically captured adherence data
- Changes in chronic therapies for cystic fibrosis following initiation of CFTR modulators: A UK retrospective cohort study 2009 - 2023
- Real-world population pharmacokinetic modeling of elexacaftor, tezacaftor, and ivacaftor
- Ensuring equity in reproductive carrier screening of CFTR with increasing population diversity
- Economic evaluation of CFTR modulator therapies in cystic fibrosis: a cost-benefit and cost-effectiveness perspective from the REMEDIA European commission project
- Stress management reduces severe depression and anxiety symptoms in adults with cystic fibrosis: Results from the coping and learning to manage stress (CALM) intervention
- A multi-center study of non-invasive colorectal cancer evaluation in cystic fibrosis (NICE-CF)
- Genotoxic pks + E. coli is strongly associated with ileocolonic neoplasia in adults with Cystic Fibrosis
- Multi-omics identification of amino acid and redox dysregulation in cystic fibrosis-related diabetes
- CFTR modulator therapy reshapes airway inflammation in cystic fibrosis: Insights from proteomics and machine learning
- Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment
- CFTR facilitates fluid secretion by ferret alveolar type 2 cells
- Partnership between cystic fibrosis centres in Europe: The Twinning Project
- Microbial content versus microbial interaction: the impact of medications on CF airway microbial ecosystems
- In Vitro Responsiveness of 417 CFTR Variants to Vanzacaftor/Tezacaftor/Ivacaftor
- A functional comparison of readthrough agent ELX-02 across a wide range of nonsense CFTR variants
- CFTR modulation alter pancreatic cancer cell growth and signaling: implications for cancer risk in cystic fibrosis
- Reducing multiple-breath washout test burden in cystic fibrosis: agreement between the first acceptable trial and mean lung clearance index
- Assessing the impact of elexacaftor/tezacaftor/ivacaftor on work productivity and activity impairment in people living with cystic fibrosis in Canada
- Epigenetic regulation and chromatin organization in cystic fibrosis airways
- Neuropsychiatric adverse effects following switch to vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: early experience from a regional centre
- Heterozygous CFTR variants associated with low-phospholipid-associated cholelithiasis phenotypes expand hepatobiliary disorders spectrum
- Extrapulmonary benefits and pharmacogenomics in lung transplant recipients with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy
- Vanzacaftor/tezacaftor/deutivacaftor partially restores CFTR function of the L467F;F508del complex allele in primary nasal epithelial cells
- Corrigendum to “Personalized therapy with CFTR modulators: Response of p.Ile148Asn variant” [J Cyst Fibros 24 (2025) 542–547]
- Long-term outcomes of adolescents/adults with CF screen positive, inconclusive diagnosis
- Timeliness to diagnostic and early care milestones after newborn screening for Cystic Fibrosis in Texas: 14 years of experience at 2 centers
- Perspectives on inhaled medicines in the CFTR modulator era: A national survey of adults with cystic fibrosis